NASDAQ
Nkarta, Inc. (NKTX)
♥ 700 Thanks from members
Nkarta, Inc. (NKTX) exhibits mixed market sentiment characterized by expanding clinical progress for its off-the-shelf CAR-NK cell therapy, NKX019, in autoimmune diseases, offset by a wider Q2 net loss, no current commercial revenue, and neutral AI/valuation hold ratings.